Paul Cacciatore
campaign leader
The Ovarian Cancer Research Fund TV Commercial Featuring Andie MacDowell
Supporters are now helping to
Campaign closed
BioMarin Pharma rejected Andrea Sloan's "compassionate use" request to obtain a novel PARP-1/2 inhibitor cancer drug known as "BMN 673." Andrea is a 7-year, stage 3c ovarian cancer survivor. Andrea, along with her M.D. Anderson doctor and the FDA, believes that this new targeted therapy may help save or extend her life. Unfortunately, Andrea can not obtain BMN 673 without BioMarin's approval. If…
We are fundraising for the Ovarian Cancer Research Fund (OCRF). OCRF is the oldest and largest charity in the U.S. funding ovarian cancer research to better diagnose, treat, and ultimately cure ovarian cancer. Join us in supporting them.
About this video
Sign In
to comment
